Dan Paterson Sells 2,000 Shares of Verastem (NASDAQ:VSTM) Stock

Verastem, Inc. (NASDAQ:VSTM - Get Free Report) CEO Dan Paterson sold 2,000 shares of the business's stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $10.50, for a total transaction of $21,000.00. Following the sale, the chief executive officer directly owned 416,818 shares in the company, valued at approximately $4,376,589. This represents a 0.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Dan Paterson also recently made the following trade(s):

• On Friday, December 5th, Dan Paterson sold 2,000 shares of Verastem stock. The stock was sold at an average price of $10.61, for a total transaction of $21,220.00.
• On Wednesday, December 3rd, Dan Paterson sold 2,000 shares of Verastem stock. The shares were sold at an average price of $10.00, for a total transaction of $20,000.00.
• On Monday, December 1st, Dan Paterson sold 2,000 shares of Verastem stock. The shares were sold at an average price of $10.39, for a total value of $20,780.00.
• On Friday, November 28th, Dan Paterson sold 2,000 shares of Verastem stock. The stock was sold at an average price of $10.79, for a total value of $21,580.00.
• On Wednesday, November 26th, Dan Paterson sold 2,000 shares of Verastem stock. The stock was sold at an average price of $10.32, for a total value of $20,640.00.
• On Monday, November 24th, Dan Paterson sold 2,000 shares of Verastem stock. The shares were sold at an average price of $10.00, for a total value of $20,000.00.
• On Friday, November 21st, Dan Paterson sold 2,000 shares of Verastem stock. The stock was sold at an average price of $10.00, for a total value of $20,000.00.
• On Monday, November 3rd, Dan Paterson sold 3,299 shares of Verastem stock. The shares were sold at an average price of $9.74, for a total value of $32,132.26.
• On Tuesday, September 16th, Dan Paterson sold 390 shares of Verastem stock. The shares were sold at an average price of $9.99, for a total transaction of $3,896.10.

Verastem Stock Down 1.3%

---

---

VSTM stock opened at $10.12 on Wednesday. The firm has a market cap of $675.81 million, a PE ratio of -2.51 and a beta of 0.41. The company has a debt-to-equity ratio of 2.06, a quick ratio of 2.55 and a current ratio of 2.58. The firm's fifty day moving average is $9.12 and its 200 day moving average is $7.73. Verastem, Inc. has a one year low of $3.45 and a one year high of $11.24.

Verastem (NASDAQ:VSTM - Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($1.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.84). The business had revenue of $11.24 million for the quarter, compared to analyst estimates of $5.76 million. On average, research analysts forecast that Verastem, Inc. will post -3.02 EPS for the current year.

Institutional Investors Weigh In On Verastem

Large investors have recently modified their holdings of the business. Woodline Partners LP purchased a new position in shares of Verastem in the third quarter worth about $2,716,000. Vivo Capital LLC increased its holdings in shares of Verastem by 71.9% in the third quarter. Vivo Capital LLC now owns 2,644,985 shares of the biopharmaceutical company's stock valued at $23,355,000 after purchasing an additional 1,106,524 shares during the last quarter. Verition Fund Management LLC purchased a new position in Verastem during the third quarter worth approximately $1,252,000. Polar Capital Holdings Plc boosted its stake in Verastem by 5.9% during the third quarter. Polar Capital Holdings Plc now owns 1,058,776 shares of the biopharmaceutical company's stock worth $9,349,000 after buying an additional 58,776 shares during the last quarter. Finally, Polymer Capital Management HK LTD purchased a new stake in Verastem in the 3rd quarter valued at $2,735,000. Hedge funds and other institutional investors own 88.37% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on VSTM. HC Wainwright reiterated a "buy" rating and set a $14.00 price target on shares of Verastem in a research report on Tuesday, October 21st. Mizuho set a $15.00 price target on shares of Verastem in a research note on Wednesday, October 29th. Cantor Fitzgerald raised shares of Verastem to a "strong-buy" rating in a report on Thursday, October 30th. BTIG Research reaffirmed a "buy" rating and set a $20.00 price objective on shares of Verastem in a report on Tuesday, September 9th. Finally, Wall Street Zen lowered shares of Verastem from a "hold" rating to a "sell" rating in a research report on Saturday, November 8th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Verastem has a consensus rating of "Moderate Buy" and an average price target of $14.29.

View Our Latest Report on Verastem

About Verastem

(Get Free Report)

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.

See Also

• Five stocks we like better than Verastem
• Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed
• Insiders Are Selling These 3 Stocks—Here’s Why
• Trading Stocks: RSI and Why it's Useful
• Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers
• Do ETFs Pay Dividends? What You Need to Know
• 10X Gains? These 3 Robotics Stocks Could Explode by 2035

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].